269 related articles for article (PubMed ID: 27927585)
21. Kaposi's Sarcoma After Autologous Stem-Cell Transplantation and Rituximab Treatment.
Geller S; Dickson MA; Busam KJ; Myskowski PL
J Oncol Pract; 2018 Sep; 14(9):565-568. PubMed ID: 30044684
[No Abstract] [Full Text] [Related]
22. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
23. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Liu Z; Markham M; Mandernach MW
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
[No Abstract] [Full Text] [Related]
25. Diagnosis and treatment of follicular lymphoma: an update.
Bargetzi M; Baumann R; Cogliatti S; Dietrich PY; Duchosal M; Goede J; Hitz F; Konermann C; Lohri A; Mey U; Novak U; Papachristofilou A; Stenner F; Taverna C; Zander T; Renner C
Swiss Med Wkly; 2018; 148():w14635. PubMed ID: 30044476
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
27. Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
Tisi MC; Paolini R; Piazza F; Ravelli E; Tecchio C; Sartori R; Famengo B; D'Amore ESG; Carli G; Perbellini O; Di Bona E; Ruggeri M; Visco C
Am J Hematol; 2018 Dec; 93(12):E386-E389. PubMed ID: 30184246
[No Abstract] [Full Text] [Related]
28. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
[No Abstract] [Full Text] [Related]
29. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report.
Ettleson M; Bongers KS; Vitale K; Perissinotti AJ; Phillips T; Marini BL
J Oncol Pharm Pract; 2019 Apr; 25(3):731-734. PubMed ID: 29385883
[TBL] [Abstract][Full Text] [Related]
30. Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
Khodarahmi I; Ghesani N
Blood; 2017 Aug; 130(9):1174. PubMed ID: 28860327
[No Abstract] [Full Text] [Related]
31. [II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2012 May; 39(5):736-42. PubMed ID: 22701900
[No Abstract] [Full Text] [Related]
32. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S
Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648
[No Abstract] [Full Text] [Related]
33. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
[No Abstract] [Full Text] [Related]
34. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW; Edwin N; Redd R; Bsat J; Chase M; LaCasce A; Freedman A; Jacobson C; Fisher D; Ng S; Crombie J; Kim A; Odejide O; Davids MS; Brown JR; Jacene H; Cashen A; Bartlett NL; Mehta-Shah N; Ghobadi A; Kahl B; Joyce R; Armand P; Jacobsen E
Blood Adv; 2020 Mar; 4(5):858-867. PubMed ID: 32126141
[TBL] [Abstract][Full Text] [Related]
35. Palatine Tonsils Primary Presentation of Blastoid Variant of Mantle Cell Lymphoma: Case Report.
Marques JAS; Ferreira F; Melo DP; Santos M; Vaz RP
Head Neck Pathol; 2021 Jun; 15(2):588-592. PubMed ID: 33091144
[TBL] [Abstract][Full Text] [Related]
36. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial.
Laurell A; Kolstad A; Jerkeman M; Räty R; Geisler CH
Leuk Lymphoma; 2014 May; 55(5):1206-8. PubMed ID: 23876100
[No Abstract] [Full Text] [Related]
37. A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Scapinello G; Riva M; Branca A; Pizzi M; Bonaldi L; Martines A; Manni S; Visentin A; Trentin L; Semenzato G; Gurrieri C; Piazza F
Ann Hematol; 2020 Nov; 99(11):2715-2717. PubMed ID: 32671454
[No Abstract] [Full Text] [Related]
38. Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma.
Puckrin R; Owen C; Street L; Perry S; Peters A; Stewart D
Leuk Lymphoma; 2023 Sep; 64(9):1596-1599. PubMed ID: 37337751
[No Abstract] [Full Text] [Related]
39. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
40. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
Albertsson-Lindblad A; Palsdottir T; Smedby KE; Weibull CE; Glimelius I; Jerkeman M
Haematologica; 2022 Mar; 107(3):740-743. PubMed ID: 34788983
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
